Carcinoembryonic Antigen (CEA)

 

Carcinoembryonic antigen (CEA), first described in 1965 by Gold and Freeman, is a tumor-associated antigen characterized as an oncofetal glycoprotein. The Healgen CEA Test is a sensitive and less complicated immunoassay of CEA. CEA was first present as a specific antigen for adenocarcinoma of the colon. More recent studies have demonstrated CEA presence in a variety of malignancies, particularly those involving ectodermal tissues of gastrointestinal or pulmonary origin. Small amounts have also been demonstrated in secretions from the colonic mucosa. Additionally, CEA-like substances have been reported in normal bile from non-icteric patients.

Cassette Buffer Dropper 2
Product NameSpecimenFormatSensitivityCatalog No.Certifications
CEA Carcinoembryonic Antigen Rapid TestSerum/PlasmaCassette5 ng/mlGECEA-302aCE Marked, not for US market
Serum/PlasmaUncut Sheet5 ng/mlGECEA-304aCE Marked, not for US market
Whole Blood/Serum/PlasmaCassette5 ng/mlGECEA-402aCE Marked, not for US market
Whole Blood/Serum/PlasmaUncut Sheet5 ng/mlGECEA-404aCE Marked, not for US market